ACTRN12611000870954已完成不适用
ACCeRT: Auckland's Cancer Cachexia evaluating Resistance Training study.EPA, Cox-2 inhibitor versus EPA, Cox-2 inhibitor, PRT plus essential amino acids intervention to assess acceptability in Non-Small-Cell Lung Cancer cachectic patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients who have diagnosed NSCLC and have received at least a first-line anti-cancer treatment e.g. surgery, chemotherapy, radiotherapy or a targeted therapy (i.e. gefitinib, erlotinib and crizotinib) and fulfil the following cachexia definition Q1 Has lost 5% of oedema-free body weight in the previous 12 months or less Q2 Mild less than or equal to 5%, Moderate greater than 10%, Severe greater than 15% Q3 If no documented weight loss, Is BMI of less than 20.0 kg/m2 Q4 At least 3 out of the following 5 1. Decreased muscle strength 2. Experiencing fatigue either measured by a VO2 max score or patient confirmed reduced physical activity 3. Anorexia 4. Low fat-free mass index (low muscle mass) 5. Abnormal biochemistry, CRP greater than 5.0mg/L IL-6 greater than 4.0pg/ml anaemia Hb less than 12.0g/dL hypoalbuminemia less than 3.2g/dL 1.Patients greater than or equal to 18 years old 2.Histologically confirmed non-small cell carcinoma of the lung. (Histological or cytological specimens must be collected via surgical biopsy, brushing, washing or core needle aspiration of a defined lesion. Sputum cytology is not acceptable) 3.Patients should be aware of the diagnosis of cancer 4. Patients able to give written informed consent obtained according to local guidelines 5.Fulfils above ‘cachectic definition’ 6.Karnofsky Scoreequal to 60 or ECOG Performance Status 0,1, 2 or 3 7.Recently completed first-line platinum-based chemotherapy 8.Lab values within the range, as defined below, within 2 weeks of randomisation: 1. Absolute neutrophils count (ANC) greater than 2.0 x 109/L 2. Platelets greater than or equal to 100 x 109/L 3. Haemoglobin greater than or equal to 100 g/dL 4. Serum creatinine less than or equal to 1.5 x ULN (= 120 micro mol/L) 5. Serum bilirubin less than or equal to 1.5 x ULN (= 25 micro mol/L) 6. Aspartate transaminase (AST) and alanine transaminase (ALT)less than or equal to 2.5 x ULN (less than or equal to 5 x ULN if liver metastases) 7. Electrolyte values (potassium, calcium, magnesium) within greater than 1 x LLN and less than 1 x ULN 8. Females of child-bearing potential must have negative serum pregnancy test (confirmation of negative urine pregnancy test within 72 hours prior to initial dosing) 9.Life expectancy greater or equal to 20 weeks
排除标准
- •1.Patients who are, in the opinion of a doctor or nurse in the department, unlikely to be suitable to participate by virtue of mental incapacity, severe current psychological or psychiatric disorder
- •2.Patients with an estimated prognosis of less than one month
- •3.Concurrent use of other investigational agents and patients who have received investigational agents in the last 4 weeks prior to randomisation
- •4.Concurrent use of other appetite stimulants e.g. MPA or MA and 4mg OD dexamethasone or 30mg OD prednisolone
- •5.Patients with systolic BP > 160 mm HG and/or diastolic > 90 mm HG
- •6.Pleural effusion that causes a CTC grade 2 dyspnoea
- •7.Radiotherapy in the last 2 weeks prior to randomisation. Patients must have recovered from all radiotherapy-related toxicities
- •8.Patients with a history of another primary malignancy within last 5 years with the exception of non-melanoma skin cancer or cervical cancer in situ
- •9.Patients having CNS metastases (Patients having any clinical signs of CNS metastases must have a CT or MRI of the brain performed to rule out CNS metastases in order to be eligible for study participation. Patients who have had brain metastases surgically removed or irradiated with no residual disease confirmed by imaging are allowed)
- •10.Patients with recent haemoptysis associated with NSCLC (> 1 teaspoon in a single episode within 4 weeks)
- •11.Patients with an abnormal Baseline 12-lead ECG
- •12.Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, chronic renal failure, chronic liver disease
- •Patient unwilling or unable to comply with the study protocol
研究者
相似试验
尚未招募
不适用
ACCORD-CRC: Australian Comprehensive Cancer Outcomes and Research Database: COLORECTAColorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12619001592134The Walter and Eliza Hall Institute of Medical Research20,000
已完成
不适用
ACTonCancer: feasibility and effectiveness of an internet- and mobile-based acceptance and commitment therapy for cancer patients - a randomized controlled pilot studyC00-C97Malignant neoplasmsDRKS00013195Abteilung für kKinische Psychologie und Psychotherapie, Institut für Psychologie undPädagogik,Universität Ulm61
招募中
不适用
ational Cancer Center Hospital (NCCH) Phase1 Liquid StudyCancerJPRN-UMIN000047567ational Cancer Center Hospital160
已完成
不适用
CCP Cancer UK Study. Companion study to educate and inform practice and guidelines regarding COVID-19 infection in cancer patientsCancer, COVID-19 (SARS-CoV-2 infection)CancerISRCTN15019599Clatterbridge Cancer Centre NHS Foundation Trust5,000
已完成
2 期
ATTAX 2Advanced oesophago-gastric cancer post docetaxel failure (second line treatment)Cancer - StomachCancer - Oesophageal (gullet)ACTRN12606000181505Australian Gastro-Intestinal Trials Group35